Your browser doesn't support javascript.
loading
Hypercalcitoninaemia in pseudohypo-parathyroidism type 1A and type 1B.
Yavropoulou, Maria P; Chronopoulos, Efstathios; Trovas, George; Avramidis, Emmanouil; Elli, Francesca Marta; Mantovani, Giovanna; Zebekakis, Pantelis; Yovos, John G.
Afiliação
  • Yavropoulou MP; 1st Propaedeutic Department of Internal Medicine, LAIKO General Hospital of Athens.
  • Chronopoulos E; 2nd Orthopaedic Department, Konstantopouleio General Hospital.
  • Trovas G; Laboratory for Research of the Musculoskeletal System, Th Garofalidis, National and Kapodistrian University of Athens, Athens, Greece.
  • Avramidis E; 2nd Orthopaedic Department, Konstantopouleio General Hospital.
  • Elli FM; Endocrinology Unit, Department of Clinical Sciences and Community Health, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.
  • Mantovani G; Endocrinology Unit, Department of Clinical Sciences and Community Health, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.
  • Zebekakis P; 1st Department of Internal Medicine, AHEPA University Hospital, Thessaloniki, Greece.
  • Yovos JG; 1st Department of Internal Medicine, AHEPA University Hospital, Thessaloniki, Greece.
Article em En | MEDLINE | ID: mdl-30703064
ABSTRACT
Pseudohypoparathyroidism (PHP) is a heterogeneous group of rare endocrine disorders characterised by normal renal function and renal resistance to the action of the parathyroid hormone. Type 1A (PHP1A), which is the most common variant, also include developmental and skeletal defects named as Albright hereditary osteodystrophy (AHO). We present two cases, a 54- and a 33-year-old male diagnosed with PHP who were referred to us for persistently high levels of serum calcitonin. AHO and multinodular goitre were present in the 54-year-old male, while the second patient was free of skeletal deformities and his thyroid gland was of normal size and without nodular appearance. We performed GNAS molecular analysis (methylation status and copy number analysis by MS-MLPA) in genomic DNA samples for both patients. The analysis revealed a novel missense variant c.131T>G p.(Leu44Pro) affecting GNAS exon 1, in the patient with the clinical diagnosis of PHP1A. This amino acid change appears to be in accordance with the clinical diagnosis of the patient. The genomic DNA analysis of the second patient revealed the presence of the recurrent 3-kb deletion affecting the imprinting control region localised in the STX16 region associated with the loss of methylation (LOM) at the GNAS A/B differentially methylated region and consistent with the diagnosis of an autosomal dominant form of PHP type 1B (PHP1B). In conclusion, hypercalcitoninaemia may be encountered in PHP1A and PHP1B even in the absence of thyroid pathology. Learning points We describe a novel missense variant c.131T>G p.(Leu44Pro) affecting GNAS exon 1 as the cause of PHP1A. Hypercalcitoninaemia in PHP1A is considered an associated resistance to calcitonin, as suggested by the generalised impairment of Gsα-mediated hormone signalling. GNAS methylation defects, as in type PHP1B, without thyroid pathology can also present with hypercalcitoninaemia.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Endocrinol Diabetes Metab Case Rep Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Endocrinol Diabetes Metab Case Rep Ano de publicação: 2019 Tipo de documento: Article